HealthEvommune scraps eczema drug after trial miss, shares plunge
Evommune said Tuesday it would abandon development of its experimental skin-disease drug after the treatment failed to meet the main goal of a mid-stage trial. The company’s shares fell 24% in after-hours trading.
R
Reuters★★☆☆☆2026-09-09 03:00Original
Evommune scraps eczema drug after trial miss, shares plunge
Health